1. Home
  2. POAS vs BIAF Comparison

POAS vs BIAF Comparison

Compare POAS & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phaos Technology Holdings (Cayman) Limited Class A Ordinary Shares

POAS

Phaos Technology Holdings (Cayman) Limited Class A Ordinary Shares

HOLD

Current Price

$0.16

Market Cap

4.6M

Sector

Industrials

ML Signal

HOLD

Logo bioAffinity Technologies Inc.

BIAF

bioAffinity Technologies Inc.

HOLD

Current Price

$15.61

Market Cap

4.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
POAS
BIAF
Founded
2017
2014
Country
Singapore
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.6M
4.5M
IPO Year
2024
2022

Fundamental Metrics

Financial Performance
Metric
POAS
BIAF
Price
$0.16
$15.61
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
160.2K
5.6M
Earning Date
05-21-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,900,000.00
Revenue This Year
N/A
$20.95
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
14.49
52 Week Low
$0.15
$0.24
52 Week High
$7.40
$13.58

Technical Indicators

Market Signals
Indicator
POAS
BIAF
Relative Strength Index (RSI) 37.69 89.05
Support Level $0.15 $1.10
Resistance Level $0.39 N/A
Average True Range (ATR) 0.01 0.86
MACD 0.01 0.91
Stochastic Oscillator 61.00 86.56

Price Performance

Historical Comparison
POAS
BIAF

About POAS Phaos Technology Holdings (Cayman) Limited Class A Ordinary Shares

Phaos Technology Holdings Cayman Ltd is an investment holding company incorporated in the Cayman Islands. Through its subsidiaries, the Company engages in the research, development, manufacturing, and commercialization of advanced optical technologies and products. Leveraging its patented microsphere technology, Phaos enhances the magnification of traditional optical microscopes, enabling visualization beyond the 200nm optical limit at a commercially viable working distance. The Company offers advanced microscopy equipment and parts, along with AI-powered software solutions that complement its hardware to deliver fully integrated microscopy systems. Its technologies serve diverse sectors, including manufacturing, biomedical, and research.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.

Share on Social Networks: